Bermekimab

Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2] As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]

Bermekimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL1A
Clinical data
Trade namesXilonix
Other namesMABp1
Routes of
administration		intravenous
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6464H10024N1736O2000S44
Molar mass145.5 g/mol g·mol−1

Bermekimab is being developed by XBiotech Inc.[5]

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
  2. Hong, David S; Hui, David; Bruera, Eduardo; Janku, Filip; Naing, Aung; Falchook, Gerald S; Piha-Paul, Sarina; Wheler, Jennifer J; Fu, Siqing; Tsimberidou, Apostolia M; Stecher, Michael; Mohanty, Prasant; Simard, John; Kurzrock, Razelle (May 2014). "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study". The Lancet Oncology. 15 (6): 656-66. doi:10.1016/S1470-2045(14)70155-X. Retrieved 3 March 2017.
  3. "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 3 March 2017.
  4. "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. U.S. National Institutes of Health. Retrieved 18 December 2018.
  5. "Xilonix™ True Human™ monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.